YE Huan,SHI Xiaohong,WU Lifeng, et al. The effect of rosuvastatin on prognosis in elderly patients with severe overlap syndrome[J]. JOURNAL OF WEZHOU MEDICAL UNIVERSITY, 2015, 45(11): 807-.
Abstract：Objective: To investigate the effect of rosuvastatin on prognosis in elderly patients with severe overlap syndrome (OS), which includes obstructive sleep apnea hypopnea syndrome (OSAHS) and chronic obstructive pulmonary disease (COPD). Methods: According to the random number table, 40 elderly patients with severe OS were randomly divided into treatment group (n=20) and control group (n=20). Rosuvastatin tablets 10 mg/qn were taken in the treatment group, while statins and other drugs which can influence blood lipid level were not taken in control group. Respectively, monitoring the parametric variation at the 1st day, 30th day, 90th day and 180th day, the parameters included triglycerides (TG), total cholesterol (TC), low density lipoprotein cholesterin (LDL-c), Lipoproteinα (LPα), apolipoprotein A1 (apoA1), apolipoprotein B (apoB), apnea hypopnea index (AHI), the mean pulse oxygen saturation (M-SaO2), the lowest pulse oxygen saturation (L-SaO2), Epworth sleepiness scale (ESS), PaCO2, PaO2, FEV1/FVC, FEV1% and the hospitalization rate of AECOPD in 180 days. Blood glucose, creatine phosphokinase, liver function and renal function, neurological abnormalities, myalgia and gastrointestinal discomfort during therapy were monitored in tow groups every month. The parameters were underwent comparison intergroup and intragroup by SPSS18.0. Results: ApoA1, M-SaO2, L-SaO2, PO2, FEV1/FVC% and FEV1% at the 30th day, 90th day and 180th day after treatment were higher than those at the 1st day in both treatment group and control group, and the differences were statistically significant (P<0.05). ApoA1, M-SaO2, L-SaO2, PO2, FEV1/FVC% and FEV1% at the 30th day, 90th day and 180th day after treatment in treatment group were higher than those in control group, and the differences were statistically significant (P<0.05). LPα, apoB, TG, TC, LDL-C, AHI, ESS and PCO2 at the 30th day, 90th day and 180th day after treatment were lower than those at the 1st day in both treatment group and control group, and the differences were statistically significant (P<0.05). LPα, apoB, TG, TC, LDL-C, AHI, ESS and PCO2 at the 30th day, 90th day and 180th day after treatment in treatment group were lower than those in control group, and the differences were statistically significant (P<0.05). The hospitalization rate of AECOPD in 180 days in treatment group were less than that in control group, and the differences were statistically significant (P<0.05). There were no abnormalities in blood glucose, creatine phosphokinase, liver function and renal function, neurological, myalgia and gastrointestinal discomfort in two groups during therapy. Conclusion: Dyslipidemia in elderly patients with severe OS can be corrected by taking rosuvastatin, which shows that rosuvastatin can improve the prognosis in elderly patients with severe OS.
[1] 叶环. 阻塞性睡眠呼吸暂停低通气综合征合并慢性阻塞性肺疾病患者脂质代谢指标及血栓前状态指标的分析[J]. 温州医科大学学报, 2014, 44(7): 503-507.
[2] 中华医学会呼吸病学分会睡眠呼吸障碍学组. 阻塞性睡眠呼吸暂停低通气综合征诊治指南(2011年修订版)[J]. 中华结核和呼吸杂志, 2012, 35(1): 9-12.
[3] 中华医学会呼吸病学分会慢性阻塞性肺疾病学组. 慢性阻塞性肺疾病诊治指南(2013年修订版)[J]. 中华结核和呼吸杂志, 2013, 36(4): 255-264.
[4] Choi HD, Shin WG. Safety and efficacy of statin treatment alone and in combination with fibrates in patients with dyslipidemia:a meta-analysis[J]. Curr Med Res Opin, 2014,30(1): 1-10.
[5] Hu M, Tomlinson B. Current perspectives on rosuvastatin[J].Integr Blood Press Control, 2013, 18(6): 15-25.
[6] Glynn RJ, Koenig W, Nordestgaard BG, et al. Rosuvastatin for primary prevention in older persons with elevated C-reactive protein and low to average low-density lipoprotein cholesterol levels: exploratory analysis of a randomized trial [J]. Ann Intern Med, 2010, 152(8): 488-496.
[7] Crouse JR, Raichlen JS, Riley WA, et a1. Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: the METEOR trial[J]. JAMA, 2007, 297(12): 1344-1353.
[8] 国希云. 瑞舒伐他汀与阿托伐他汀治疗老年高脂血症患者临床疗效的比较[J]. 中华老年心脑血管病杂志, 2014, 16(6): 605-607.
